Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds

Ocular Therapeutix (OCUL) is a highly favored stock by hedge funds due to its potential to address unmet needs in retinal diseases. The company's portfolio includes DEXTENZA, AXPAXLI in phase 3 clinical trial, and OTX-TIC in phase 2 clinical trial. Analysts have raised price targets on OCUL, citing positive data from the SOL-1 trial and strong efficacy and safety profiles. The stock has an upside potential of over 257% according to Bank of America Securities and 28% according to Clear Street.